Table 1.
Baseline and postoperative characteristics in relation to peri-procedural (≤7 days) new-onset AF among patients undergoing cardiac surgery in the LAACS study
| Variable | No AF (n=83) | New-onset AF (n=80) | p-value |
|---|---|---|---|
| Age, years | 65.3±10.1 | 70.5±7.7 | <0.001 |
| Male | 71 (85.5) | 66 (82.5) | 0.60 |
| Clinical characteristics | |||
| Congestive heart failure | 13 (15.7) | 15 (18.8) | 0.65 |
| Diabetes | 22 (26.5) | 21 (26.3) | 0.96 |
| Hypertension | 60 (72.3) | 63 (78.8) | 0.32 |
| CHA2DS2-VASc, unit | 2.7±1.5 | 3.3±1.4 | 0.01 |
| Prior stroke | 9 (10.8) | 14 (17.5) | 0.27 |
| Chronic kidney diseasea | 9 (10.8) | 17 (21.3) | 0.13 |
| Medicine | |||
| ASA | 68 (81.9) | 67 (83.8) | 0.86 |
| Clopidogrel | 16 (19.3) | 12 (15.0) | 0.55 |
| Beta blocker | 48 (57.8) | 49 (61.3) | 0.75 |
| Verapamil | 2 (2.4) | 2 (2.5) | 1.00 |
| Calcium blocker | 18 (21.7) | 32 (40.0) | 0.01 |
| RAS blocker | 46 (55.4) | 37 (46.3) | 0.27 |
| Discharged with OAC | 20 (24.1) | 31 (38.8) | 0.04 |
| Statin | 70 (84.3) | 67 (83.8) | 0.97 |
| Procedural characteristics | |||
| Left atrial appendage closure (randomized) | 51 (61.4) | 32 (40.0) | 0.02 |
| Surgery type | |||
| AVR only | 11 (13.3) | 15 (18.8) | 0.34 |
| AVR with CABG | 13 (16.3) | 21 (26.3) | 0.09 |
| AVR with aortic surgery | 1 (1.2) | 1 (1.3) | 1.00 |
| AVR with MVR | 1 (1.2) | 1 (1.3) | 1.00 |
| Aortic surgery only | 1 (1.2) | 0 (0) | 1.00 |
| CABG only | 52 (62.7) | 34 (42.5) | 0.01 |
| CABG with MVR | 2 (2.4) | 1 (1.3) | 0.58 |
| MVR only | 2 (2.4) | 7 (8.8) | 0.13 |
| Tricuspid surgery only | 0 (0) | 0 (0) | 1.00 |
Notes:
a
eGFR<30 mL/min. Data presented as n (%) or mean ± SD.
Abbreviations: AF, atrial fibrillation; ASA, acetyl salicylic acid; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CHA2DS2-VASc, congestive heart failure, hypertension, age (≥75 years), diabetes, stroke – peripheral vascular disease, age (≥65 years), sex category; eGFR, estimated glomerular filtration rate; LAACS, Left Atrial Appendage Closure with Surgery; MVR, mitral valve repair or replacement; OAC, oral anticoagulation; RAS, renin–angiotensin system.